NCM
EDIT icon

Next Capital Management’s Editas Medicine EDIT Stock Holding History

Next Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-165
Closed -$4K – 410
2019
Q2 		$4K Buy
+165
New +$3.94K ﹤0.01% 692

Other funds holding EDIT

NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Next Capital Management's EDIT Position: Q3 2019 in Review

Next Capital Management sold out of Editas Medicine (EDIT) in Q3 2019, closing a stake of 165 shares — an estimated $4K sold.

Next Capital Management first reported a position in EDIT in Q2 2019 and held it in 1 quarter. The position peaked at $4K in Q2 2019. 187 funds tracked by Wall St. Rank hold EDIT as of Q3 2019.

  • Next Capital Management reported no remaining Editas Medicine position as of Q3 2019 after selling out during the quarter.
  • Next Capital Management sold 165 Editas Medicine shares in Q3 2019, an estimated $4K.
  • Next Capital Management first reported a position in Editas Medicine in Q2 2019 and held it in 1 quarter.
  • Next Capital Management's Editas Medicine position peaked at $4K in Q2 2019.
  • 187 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2019.

Based on Next Capital Management's 13F filing for Q3 2019, filed 12 Nov 2019.